Prime Therapeutics applauds new legislation to drive greater biosimilar uptake, lower total cost of care

EAGAN, Minn., April 26, 2021 /PRNewswire/ — Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM) serving approximately 33 million members nationally, released the following statement in response to the recent enactment of “The Ensuring Innovation Act” and the “Advancing Education on Biosimilars Act of 2021” by the U.S. Congress. The Acts are intended to increase availability of biosimilars by removing barriers or loopholes that prevent adoption:

“We applaud the President of the United States and Congress today as two bills were signed into law that will help address high drug prices by removing barriers that currently prevent greater adoption of biosimilars,” said Joseph Leach, MD, chief medical officer of Prime Therapeutics. 

Dr. Leach added, “‘The Ensuring Innovation Act’ and the ‘Advancing Education on Biosimilars Act of 2021′ are a much-needed boost to help normalize use of biosimilars, just as generics were normalized years ago. Prime has long supported use of biosimilars. Prime has taken measures to manage to the lowest net-cost therapeutic options and recently worked with its Pharmacy and Therapeutics Committee to endorse a position that creates a pathway for Prime’s health plans to prefer the use of biosimilars whenever appropriate.

“With more biosimilars coming to market creating increased competition for various therapy classes, now is the time to double down on any and all efforts to encourage further use of biosimilars,” noted Dr. Leach. “Prime is well positioned to help our clients with biosimilar adoption in their local and regional markets. Biosimilar education for providers and patients will help increase adoption and improve cost savings, so leveraging HHS’s educational materials will be a great reinforcement. We’re driving toward total drug management solutions that include biosimilar uptake. Bottom line, we see great value in focusing on any and all steps that can pave the road toward faster adoption and lowering of prescription drug costs for health plans, employers and patients, and as a pharmacy benefit manager committed to lowest total cost of care we stand ready to support the administration.”

About Prime Therapeutics
Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and offers clinical services for people with complex medical conditions. Prime serves approximately 33 million people. It is collectively owned by 19 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans. For more information, visit www.primetherapeutics.com or follow @PrimePBM on Twitter.

Contact:

Karen Lyons, APR

Senior Director of Public Relations

612.777.5742

[email protected]

 

Cision View original content:http://www.prnewswire.com/news-releases/prime-therapeutics-applauds-new-legislation-to-drive-greater-biosimilar-uptake-lower-total-cost-of-care-301277134.html

SOURCE Prime Therapeutics LLC

Prime Therapeutics applauds new legislation to drive greater biosimilar uptake, lower total cost of care WeeklyReviewer

PR Newswire Political/Government News

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

WeeklyReviewer earns commissions through affiliates of qualifying products through Amazon Associates, Fiverr Affiliates, Hostgator Affiliates, Namecheap Affiliates, NordVPN Affiliates, Semrush Affiliates, Alibaba Affiliates, Clickfunnels Affiliate, Leadpages Affiliates, Cryptohopper Affiliates, Binance Affiliates and more.

Clicking on links in WeeklyReviewer may or may not provide us commission through any qualifying purchases.

Prime Therapeutics applauds new legislation to drive greater biosimilar uptake, lower total cost of care WeeklyReviewer
World Reviewer Staffhttps://weeklyreviewer.com/
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Related articles

WeeklyReviewer